How could a baby get an organ from a person living with HIV and not automatically contract the virus? The experts weigh in.
- Published
- 09 October 2018
- From
-
Bhekisisa
Outreach workers identify a number of personal, social, and structural challenges that impede efforts to prevent mother-to-child transmission of HIV in India.
- Published
- 05 October 2018
- From
-
AVERT
Exposure to protease inhibitor (PI)-based regimens and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may
each be linked to low birth weight and pre-term births in infants
- Published
- 03 September 2018
- By
- Keith Alcorn
Women with HIV on effective antiretroviral treatment in higher-income settings who
have undetectable viral load should be supported to make their own decisions
about breastfeeding based on
- Published
- 23 August 2018
- By
- Keith Alcorn
Among 60 women presenting to routine antenatal clinics in Kampala, Uganda and Cape Town, South Africa with undiagnosed HIV in late pregnancy, viral load suppression
- Published
- 31 July 2018
- By
- Carole Leach-Lemens
Africa is far off track in reducing new HIV infections among
children and young people and is unlikely to reduce new infections in young people
substantially before
- Published
- 26 July 2018
- By
- Keith Alcorn
It's already clear that the story from Amsterdam is that ending epidemic levels of new HIV diagnoses depends on building services and societies that recognize individuals as wonderful, wild, weird, whole people, with more specificity, respect and rigor than ever before. It also depends on activism, nasty women and their male allies, everyone demanding change, refusing to play nice.
- Published
- 26 July 2018
- From
-
AVAC
Dolutegravir treatment at the time of conception is associated with a higher risk of neural tube defects in infants exposed to the drug when compared
- Published
- 24 July 2018
- By
- Keith Alcorn
New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.
- Published
- 18 July 2018
- From
-
MHRA
The news in May 2018 of a potential risk of neural tube defects in infants born to women taking dolutegravir (DTG) at the time of conception sent shockwaves through the HIV community. But, despite massive global investment, aggressive transition plans – as well as calls for years for more systematic recording of outcomes when women receive ART in pregnancy– few prospective birth registrieshave been established in other settings that can refute or confirm this finding. Meanwhile, women of child-bearing age, whether they intend to become pregnant or not, are being told that they must stick with (or go back to) efavirenz (EFV) – a drug that, before this news, was in the process of being replaced with DTG.
- Published
- 16 July 2018
- From
-
HIV i-Base
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...